摘要
目的:分析阿德福韦酯与恩替卡韦分别联合长效干扰素治疗e抗原阳性慢性乙肝的效果。方法:选取本院2014年8月-2018年3月收治的140例e抗原阳性慢性乙肝患者进行研究,按随机数字表法将其分为观察组与对照组,各70例。所有患者均给予聚乙二醇干扰素a-2a治疗,在此基础上,观察组联合恩替卡韦治疗,对照组联合阿德福韦酯治疗。治疗48周后比较两组患者的治疗效果、肝功能改善情况及并发症发生情况。结果:两组患者ALT复常率、HBeAg转换率及HBsAg转阴率比较,差异均无统计学意义(P>0.05)。观察组HBeAg转阴率及HBV DNA转阴率均高于对照组,差异均有统计学意义(P<0.05)。治疗后,两组患者ALT、AST、ALB和TBIL均较治疗前明显改善,差异均有统计学意义(P<0.05)。治疗前后两组肝功能指标比较,差异均无统计学意义(P>0.05)。两组患者不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:联合聚乙二醇干扰素a-2a治疗e抗原阳性慢性乙肝时,恩替卡韦疗效优于阿德福韦酯,但两者对肝功能的改善作用和安全性相近。
Objective:To investigate the treatment effects of Adefovir and Entecavir combined with Peginterferon a-2 a in the treatment of HBeAg positive chronic hepatitis B.Method:140 cases of HBeAg positive chronic hepatitis B were selected in our hospital from August 2014 to March 2018,and they were divided into observation group and control group according to random number table,70 cases in each group.All patients were treated with Peginterferon a-2 a,on this basis,the observation group was treated with Entecavir and the control group was treated with Adefovir,after 48 weeks of treatment,the therapeutic effect,liver function and the occurrence of adverse reactions of the two groups were compared.Result:After treatment,there were no significant differences in ALT normalization rate,HBeAg conversion rate and HBsAg negative conversion rate between the two groups(P>0.05).The negative rates of HBeAg and HBV DNA in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).After treatment,ALT,AST,ALB and TBIL in the two groups were significantly improved compared with those before treatment,the differences were statistically significant(P<0.05).There were no significant differences in liver function between the two groups before and after treatment(P>0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Entecavir is superior to Adefovir in the treatment of HBeAg positive chronic hepatitis B,but both have similar effect and safety in improving liver function.
作者
方阳阳
FANG Yangyang(Jiamusi Infectious Diseases Hospital,Jiamusi 154007,China)
出处
《中国医学创新》
CAS
2019年第17期63-66,共4页
Medical Innovation of China
